Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

Journal of Clinical Oncology

Volumn 20, Issue 2, 2002, Pages 405-412

  Levine, John E ^a   Braun, Thomas ^a   Penza, Samuel L ^a   Beatty, Patrick ^a   Cornetta, Kenneth ^a   Martino, Rodrigo ^a   Drobyski, William R ^a   Barrett, A John ^a   Porter, David L ^a   Giralt, Sergio ^a   Leis, Jose ^a   Holmes, Houston E ^a   Johnson, Matthew ^a   Horowitz, Mary ^a   Collins Jr , Robert H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CLADRIBINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHILD; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REMISSION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, MYELOID; LEUKOCYTES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0037080121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.2.405     Document Type: Article

References (31)

1. Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
2. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy
3. Second transplants for leukaemic relapse after bone marrow transplantation: High early mortality but favourable effect of chronic GVHD on continued remission
4. Induction of graft-verus-host disease as immunotherapy for relapsed chronic myeloid leukemia
5. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
6. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
7. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin- 2 to treat leukemia relapse after allogeneic bone marrow transplantation
8. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
9. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukemia patients treated for relapse after allogeneic bone marrow transplantation
10. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation
11. Donor leukocyte transfusions for treatment of leukemic relapses after bone marrow transplantation
12. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
13. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
14. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation
15. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
16. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia
17. Bone marrow transplantation
18. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
19. Kaplan-Meier, marginal, or conditional probability curves in summarizing competing risks failure time data
20. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy
21. Relapse after allogeneic bone marrow transplantation for acute leukemia: A survey by the EBMT of 117 cases
22. Second HLA-identical transplants for leukemia recurrence
23. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Societé Française de Greffe de Moelle (SFGM)
24. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse
25. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation
26. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation
27. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation
28. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
29. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease
30. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient
31. Graft-versus-leukemia reactions after bone marrow transplantation